All News

moneyglobe.jpg

Medicare's 'Most Favored Nation' Drug-Pricing Rule in Limbo

d MedPage Today

The fate of the Trump administration's "most favored nation" (MFN) rule for bringing down prescription drug prices remains uncertain as President-elect Joe Biden prepares to assume office later this month.

Read Article
FINAL 2020 Podcast Graphic

RheumNow Podcast – Lights, Camera, Zoom (1.8.2021)

d Jack Cush, MD

Dr. Jack Cush reviews the news, journal articles and favorite blogs from this past week on RheumNow.com.

Read Article
pill pillbox adherence

Adherence to Hydroxychloroquine Lowers Lupus Mortality

d Jack Cush, MD

A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. 

Read Article
cardiac2.jpg (keep)

Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis

d Jack Cush, MD

Recurrent pericarditis is a rare, probable autoinflammatory disorder mediated by interleukin-1 (IL-1); and is often refractory to glucocorticoids and colchicine.

Read Article
pills.bottle.hand__0.jpg

EULAR Guidance on Patient Adherence to Meds

d Jack Cush, MD

Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease.  It has been estimated that 30-80% of patients with rheumatic and musculoskeletal diseases (RMDs) are nonadherent to prescribed regimens.  EULAR has commissioned a task force

Read Article
Adherence to Hydroxychloroquine Lowers Lupus Mortality A lupus cohort study from British Columbia, Canada has shown that medication adherence with hydroxychloroquine (HCQ) is associated with a 71% to 83% lower mortality. Read more... https://t.co/luoot7sZZl https://t.co/i2qrqU4EDy

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats – top presentations in Still’s disease Sponsored by Novartis Medical Affairs Unable to attend all the key sessions at ACR Convergence 2020? Listen to the experts as they present their views on the top abstracts. https://t.co/MD6lU5oIvy https://t.co/wGVUI5Xjkk

Links:

Dr. John Cush RheumNow ( View Tweet)
ACR Convergence 2020 Fireside Chats- top presentations in nr-axSpA, AS, axial PsA and Still’s disease. Sponsored by Novartis Medical Affairs Unable to attend the key sessions at #ACR20? Listen to the experts as they weigh in on the top abstracts. https://t.co/bFrbEGtnw3 https://t.co/dMqhX0f6te

Links:

Dr. John Cush RheumNow ( View Tweet)
Rhapsody Study: IL-1 Inhibition in Recurrent Pericarditis RHAPSODY was a phase 3 multicenter, double-blind, event-driven, randomized-withdrawal trial of rilonacept in 86 patients with recurrent pericarditis Read more: https://t.co/syibq4X7Ps https://t.co/gnxlpOGiHA

Links:

Dr. John Cush RheumNow ( View Tweet)
EULAR Guidance on Patient Adherence to Meds--Non-adherence may be the single most untold risk to suboptimal outcomes in the care of musculoskeletal disease. https://t.co/XwxkFz66fv https://t.co/E6W3H56jps

Links:

Dr. John Cush RheumNow ( View Tweet)
Petri et al shows higher HCQ levels associated with reduced thrombosis risk, study of 739 SLE pts - 38 patients (5.1%) had thrombosis. HCQ level lower in thrombosis pts (720 vs 935, p=0.025). 69% decr in VTE when levels >1068 ng/mL vs <648 ng/mL https://t.co/kis5zry7uH

Links:

Dr. John Cush RheumNow ( View Tweet)

Head to RheumNow for our latest Covid-19 articles. https://t.co/TiB7739ONL

Links:

Dr. John Cush RheumNow ( View Tweet)

New download available! H2H comparison chart. https://t.co/w7tQYXn0us

Links:

Dr. John Cush RheumNow ( View Tweet)

Spinal Benefits Seen With Cosentyx in PsA---Secukinumab (Cosentyx) was effective for axial manifestations of psoriatic arthritis in a 52-week multicenter phase III study, investigators reported. https://t.co/OfkQtAO9Gh https://t.co/hs3NaBjLuF

Links:

Dr. John Cush RheumNow ( View Tweet)
BASE: a controlled, ph 4 safety RCT of IV Belimumab (10 mg/kg) or PBO (+standard Rx) given to 4018 SLE pts over 48 wks. Found no increase in all-cause mortality and special AE: w/ very low event rates (SIE 3·75%, opportunistic infx 1·8%, cancers 0·25%) https://t.co/Zc5BqXQ038

Links:

Dr. John Cush RheumNow ( View Tweet)

44 patient study of sirolimus vs placebo in patients with inclusion body myositis found no difference in the primary outcome of relative knee extension strength, nor in secondary outcomes. SAE were more common w/ sirolimus 45% vs 27% in PBO https://t.co/YhnRTnaGFl

Links:

Dr. John Cush RheumNow ( View Tweet)

2021 Whatever it Takes Let me be blunt. If you’re still waiting for this whole COVID thing to be over with – you’re drifting, going nowhere and you’re setting yourself up for a long hard winter, spring and summer of 2021. Read more on the site. https://t.co/1y172EVpwV https://t.co/W1MAKzOCJS

Links:

Dr. John Cush RheumNow ( View Tweet)
Nice Yale Medicine overview of MIS-C (multisystem inflammatory syndrome in children) due to COVID-19 https://t.co/oYOlJFHzuN

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID-19 Vaccination - Phase Ib Begins The U.S. Centers for Disease Control and Prevention (CDC) has issued a timeline guidance document on when, how and who should get the commercially available COVID-19 vaccines. https://t.co/7fGCnHJnvy https://t.co/AiBBW94kR5

Links:

Dr. John Cush RheumNow ( View Tweet)
Broadalumab the other IL-17 inhibitor, is FDA approved for psoriasis. The AMVISION-1 & AMVISION-2 ph III trials in psoriatic arthritis showed in 962 PsA pts it was effective w/ week 16 ACR20 of ~46% (vs 21% PBO). AEs unremarkable w/ 1 case of depression https://t.co/zrsVD7N3Z9

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×